Navigation Links
DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics

Data supports potential use of DIO-902 with Atorvastatin

SAN FRANCISCO, April 1, 2008 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that a scientific poster relating to DIO-902 (levdexketoconazole) is being presented at the American Society for Clinical Pharmacology and Therapeutics annual meeting on Saturday, April 5th in Orlando. DIO-902 is being studied in Phase 2b clinical trials for the treatment of type 2 diabetes.

The poster, entitled "Differential Effects of Co-Administration of Racemic Ketoconazole and Levdexketoconazole on the Pharmacokinetic Profile of Atorvastatin," highlights the results of a study evaluating the effects of equal doses of the single enantiomer DIO-902 and racemic ketoconazole, on the pharmacokinetics of a single 80 mg dose of atorvastatin in healthy volunteers. Overall, repeated oral administration of DIO-902 tablets with atorvastatin was safe and well tolerated; in addition, DIO-902 significantly reduced cortisol levels compared with ketoconazole.

"The increase in total exposure of atorvastatin was significantly less when it was administered with DIO-902 than with racemic ketoconazole," said Dr. Tim Stewart, Vice President of Research at DiObex. "In addition, the administration of DIO-902 with atorvastatin resulted in significantly reduced cortisol levels from placebo, compared with atorvastatin administered with racemic ketoconazole. This finding supports preclinical evidence that DIO-902 is a more potent inhibitor of cortisol synthesis than ketoconazole."

DIO-902 is an oral, single enantiomer of ketoconazole, a common anti-fungal drug. DiObex is developing DIO-902 as a novel cortisol inhibitor for treating type 2 diabetes and diabetic nephropathy. There is growing evidence linking abnormal cortisol metabolism to both type 2 diabetes and metabolic syndrome, prompting a search for therapeutic agents that lower levels of cortisol or block the effects of cortisol excess. Preclinical and clinical data indicate that DIO-902 is a potent cortisol inhibitor. Clinical data also show early trends toward reductions in HbA1c, total cholesterol, LDL cholesterol, and C-reactive protein. Preclinical and clinical data also suggest that DIO-902 may be a safer and more effective agent than racemic ketoconazole.

About DiObex

DiObex, Inc. is a privately held biotechnology company developing novel products for diabetes and metabolic diseases. DiObex has two product candidates in four mid-stage clinical development programs. DIO-901 (very low dose glucagon) is in development for the prevention of insulin-induced hypoglycemia in type 1 diabetes mellitus in an extended release subcutaneous formulation and in a convenient disposable subcutaneous delivery device. DIO-901 has received Fast Track status from the FDA. DIO-902 (levdexketoconazole) is an oral, single enantiomer of ketoconazole that is a novel cortisol synthesis inhibitor in development for type 2 diabetes mellitus and diabetic nephropathy. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for type 2 diabetes mellitus and cardiovascular disease. For more information, visit

SOURCE DiObex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
2. DiObex, Inc. to Present at Merrill Lynch Global Healthcare Conference
3. DiObex Inc. to Present at BIO Mid-America Venture Forum
4. DaVita Announces Retirement of Former Chief Medical Officer Charles J. McAllister, M.D.
5. Human Pheromone Sciences Announces Quarterly and Full Year Results
6. Dragon Pharma announces 2007 full year financial results
7. Genaera Corporation Announces 2007 Financial Results
8. Genmab Announces Year End 2007 Financial Results
9. Immunosyn Corporation Announces 2007 Results, Files 10KSB
10. Elbit Imaging Ltd. Announces Results For Fiscal Year 2007
11. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
Post Your Comments:
(Date:11/24/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended September 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of iCo ... value enriching for this clinical program, but also ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
Breaking Biology Technology:
(Date:11/17/2015)... 17, 2015 Pressure BioSciences, Inc. (OTCQB: PBIO) ... and sale of broadly enabling, pressure cycling technology ("PCT")-based ... today announced it has received gross proceeds of $745,000 ... Placement (the "Offering"), increasing the total amount raised to ... additional closings are expected in the near future. ...
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
Breaking Biology News(10 mins):